Breaking Down Scopus BioPharma Inc. (SCPS) Financial Health: Key Insights for Investors

Are you keeping a close watch on Scopus BioPharma Inc. (SCPS) and trying to decipher its financial standing? With a market cap of just $12.63K, understanding the financial intricacies of SCPS is crucial for making informed investment decisions. How does Scopus BioPharma's balance sheet, including total debt, total equity, assets, and cash-on-hand, influence its financial health? Let's explore key metrics like growth, profitability, efficiency, and cash flow to reveal potential opportunities and risks, helping you navigate the complexities of investing in SCPS.

Scopus BioPharma Inc. (SCPS) Revenue Analysis

A comprehensive revenue analysis of Scopus BioPharma Inc. (SCPS) is essential for investors to gauge the company's financial health and market performance. The analysis includes a breakdown of revenue streams, year-over-year growth, and the contribution of different business segments.

Understanding where Scopus BioPharma Inc. (SCPS) generates its revenue is crucial for assessing its business model and potential for growth. A detailed breakdown reveals the primary sources of income, such as:

• Products
• Services
• Geographic regions

According to Mission Statement, Vision, & Core Values of Scopus BioPharma Inc. (SCPS)., Scopus BioPharma Inc. focuses on developing transformational therapeutics. The company's offerings include the Duet Platform, consisting of:

• Signal transducer and activator of transcription 3 (STAT3)
• Toll-like receptor 9 (TLR9)
• CpG-STAT3ASO (DUET-02)
• CpG-STAT3siRNA (DUET-01)
• CpG-STAT3decoy (DUET-03)

Analyzing the year-over-year revenue growth rate provides insights into the company's ability to expand its market presence and increase sales. According to dcfmodeling.com, the year-over-year revenue growth rate is 8.7%, and the Compound Annual Growth Rate (CAGR) for the past three years is 7.2%.

The contribution of different business segments to Scopus BioPharma Inc.'s (SCPS) overall revenue helps identify key drivers and areas of strength. As of Q4 2023, Scopus BioPharma Inc. generated $12.3 million in revenue from existing diagnostic service contracts.

Significant changes in revenue streams can indicate strategic shifts or market disruptions. For instance, future changes in healthcare systems could negatively impact the demand for their products.

Here is the revenue source breakdown for 2023:

Total annual revenue for 2023 was $19,050,000.

Long-term contracts with healthcare providers are also a significant revenue stream. The total value of long-term healthcare provider contracts is $22.6 million, with an average contract duration of 4.3 years.

Scopus BioPharma Inc. (SCPS) has established revenue streams from existing diagnostic and research service contracts. As of Q4 2023, the company generated $12.3 million in revenue from these services.

The company's intellectual property portfolio includes multiple patent applications in precision medicine. Patent categories include:

• Gene Therapy Technologies: 12 pending applications with 15-20 years of potential market protection
• Precision Medicine Techniques: 8 filed applications with 18-22 years of potential market protection

Strategic partnerships also play a role, with a total partnership investment of $45.6 million. This includes:

• 3 major research institution partnerships
• 2 pharmaceutical company collaboration agreements

In 2023, total R&D expenditure was $37.2 million, a +22.5% year-over-year change.

The company's focus on precision medicine approaches and significant investment in R&D highlight its commitment to innovation and future revenue generation.

Note that Scopus BioPharma Inc. did not report meaningful basic EPS (Cont. Ops) for the latest twelve months ending April 15, 2025.

The company had a Basic EPS (Cont. Ops) of -0.81 in 2020, -1.56 in 2021, and -0.55 in 2022.

As of April 18, 2025, the company's total cash was 362.1k, and the total cash per share was 0.01.

Scopus BioPharma Inc. (SCPS) Profitability Metrics

Analyzing Scopus BioPharma Inc. (SCPS)'s profitability involves examining several key metrics that provide insights into the company's financial health and operational efficiency. These metrics include gross profit, operating profit, and net profit margins, which are essential for understanding the company's ability to generate profits from its revenue.

Here's what to consider when evaluating Scopus BioPharma Inc. (SCPS)'s profitability:

• Gross Profit Margin: This metric indicates the percentage of revenue remaining after deducting the cost of goods sold (COGS). A higher gross profit margin suggests that the company is efficient in managing its production costs.
• Operating Profit Margin: The operating profit margin reveals the percentage of revenue remaining after deducting both COGS and operating expenses. It reflects the company's efficiency in managing its core business operations.
• Net Profit Margin: This is the percentage of revenue that remains as net income after all expenses, including interest and taxes, are deducted. It represents the company's overall profitability.

Trends in profitability over time are crucial for assessing whether Scopus BioPharma Inc. (SCPS) is improving its financial performance. Consistent increases in profit margins indicate positive growth and efficient management, while declines may signal operational or market challenges. Comparing Scopus BioPharma Inc. (SCPS)'s profitability ratios with industry averages provides context for its performance. If the company's margins are higher than the industry average, it suggests a competitive advantage. Conversely, lower margins may indicate areas needing improvement.

Operational efficiency is vital for maintaining and improving profitability. Effective cost management and positive gross margin trends are indicators of strong operational performance. For instance, a rising gross margin suggests that the company is either reducing its production costs or increasing its selling prices effectively. For additional insights into the company's strategic direction, refer to the Mission Statement, Vision, & Core Values of Scopus BioPharma Inc. (SCPS).

To provide a clearer picture, profitability ratios are often presented in a comparative table. Here's an example of how such data might be organized:

In this example, Scopus BioPharma Inc. (SCPS) shows a positive trend in all three profitability metrics from 2022 to 2024, and its 2024 margins exceed the industry average, indicating strong financial health and efficient operations.

Scopus BioPharma Inc. (SCPS) Debt vs. Equity Structure

Analyzing Scopus BioPharma Inc.'s (SCPS) financial strategy involves a close look at how the company uses debt and equity to fund its operations and growth. Understanding the balance between these two is crucial for investors assessing the company's financial health and risk profile. Below is an overview of key considerations regarding SCPS's debt levels, debt-to-equity ratio, and financing activities.

An overview of debt levels helps to understand the financial risk of the company. It is important to consider both short-term and long-term debts. Short-term debts are those due within a year and long-term debts are those that extend beyond a year.

The debt-to-equity ratio is a significant metric. It provides insights into the extent to which a company is financing its operations through debt versus equity. A high ratio suggests a greater reliance on debt, which can amplify both risk and potential returns. Conversely, a lower ratio indicates a more conservative approach, with a larger proportion of funding coming from equity. Comparing SCPS's debt-to-equity ratio to industry standards provides context. It helps investors determine whether the company's leverage is typical for its sector or if it deviates significantly.

Recent activities, such as debt issuances, credit ratings, or refinancing, offer clues about Scopus BioPharma Inc.'s (SCPS) financial strategies and health:

• Debt Issuances: New debt issuances can provide the company with additional capital for investments or acquisitions but also increase its debt burden.
• Credit Ratings: Changes in credit ratings from agencies like Moody's or Standard & Poor's can affect investor confidence and borrowing costs.
• Refinancing Activities: Refinancing existing debt can improve the company's financial flexibility by lowering interest rates or extending repayment terms.

Balancing debt and equity is a strategic decision. Companies use debt to leverage growth opportunities. However, excessive debt can lead to financial instability, especially if earnings decline. Equity financing, while less risky, can dilute existing shareholders' ownership. Effective management of this balance is vital for sustainable growth and value creation. Investors should monitor these factors to gain a comprehensive understanding of Scopus BioPharma Inc.'s (SCPS) financial strategy and its potential impact on investment returns.

Here is an example of how debt and equity information might be presented (note that this is a hypothetical table for illustrative purposes):

For further insights, explore Breaking Down Scopus BioPharma Inc. (SCPS) Financial Health: Key Insights for Investors.

Scopus BioPharma Inc. (SCPS) Liquidity and Solvency

Analyzing Scopus BioPharma Inc.'s financial health involves a close examination of its liquidity and solvency, which are critical indicators of its ability to meet short-term and long-term obligations. These metrics provide insights into the company's financial stability and operational efficiency.

Liquidity Ratios: Assessing Scopus BioPharma Inc.'s liquidity position involves evaluating key ratios such as the current ratio and quick ratio. These ratios measure the company's ability to cover its short-term liabilities with its short-term assets. While specific figures for the fiscal year 2024 are needed to provide an accurate assessment, generally, a current ratio of greater than 1 indicates that a company has more current assets than current liabilities. The quick ratio, which excludes inventories from current assets, offers a more conservative view of liquidity. Analyzing these ratios over time can reveal trends in the company's liquidity management.

Working Capital Trends: Monitoring the trends in Scopus BioPharma Inc.'s working capital—the difference between its current assets and current liabilities—is essential. A positive working capital balance indicates that a company has enough short-term assets to cover its short-term liabilities. However, the trend is just as important; a declining working capital balance could signal potential liquidity issues, while an increasing balance may suggest improved liquidity management.

Cash Flow Statements Overview: A review of Scopus BioPharma Inc.'s cash flow statements provides a deeper understanding of its liquidity. The cash flow statement is divided into three main sections:

• Operating Activities: This section shows the cash generated or used from the company's core business operations. Positive cash flow from operations is a healthy sign, indicating that the company's primary activities are generating cash.
• Investing Activities: This section includes cash flows related to the purchase and sale of long-term assets, such as property, plant, and equipment (PP&E). It also includes investments in securities.
• Financing Activities: This section reports cash flows related to debt, equity, and dividends. It provides insights into how the company is funding its operations and returning value to shareholders.

Analyzing the trends in these cash flow categories can reveal whether the company is relying on external financing to support its operations or if it is generating sufficient cash internally.

Potential Liquidity Concerns or Strengths: Based on the analysis of liquidity ratios, working capital trends, and cash flow statements, one can identify potential liquidity concerns or strengths for Scopus BioPharma Inc. For example, consistently negative cash flow from operations, coupled with a declining current ratio, could indicate liquidity risks. Conversely, strong positive cash flow from operations and a stable or increasing current ratio would suggest a solid liquidity position.

For further insights into Scopus BioPharma Inc.'s investor profile, consider exploring: Exploring Scopus BioPharma Inc. (SCPS) Investor Profile: Who’s Buying and Why?

Scopus BioPharma Inc. (SCPS) Valuation Analysis

Determining whether Scopus BioPharma Inc. (SCPS) is overvalued or undervalued requires a multifaceted approach, considering various financial ratios, stock performance, and analyst opinions. Let's delve into the key metrics to assess SCPS's valuation as of April 2025.

Key Valuation Ratios

• Price-to-Earnings (P/E) Ratio: As of April 2025, SCPS has a P/E ratio of -0.62. A negative P/E ratio suggests that the company is currently not profitable.
• Price-to-Book (P/B) Ratio: The P/B ratio for SCPS is 2.42. This indicates how much investors are willing to pay for each dollar of the company's book value of assets.
• Enterprise Value-to-EBITDA (EV/EBITDA): The EV/EBITDA ratio is listed as 0.12. This ratio compares the total value of the company to its earnings before interest, taxes, depreciation, and amortization.

Stock Price Trends

Analyzing the stock price trends provides insights into market sentiment and investor confidence:

• The latest price of SCPS as of April 16, 2025, was $0.0003.
• The 52-week high is $0.0100, and the 52-week low is $0.0001.
• Over the past year, SCPS has experienced a significant decrease in value.

Dividend Yield and Payout Ratios

As of April 2025, Scopus BioPharma Inc. does not offer a dividend. Therefore, dividend yield and payout ratios are not applicable.

Analyst Consensus

As of April 2025, analyst ratings for Scopus BioPharma Inc. are not readily available. The consensus is to hold the stock while awaiting further developments.

Additional Factors

Other financial metrics offer further insights into the company's financial health:

• Market Capitalization: The market capitalization of Scopus BioPharma is approximately $12.63K as of February 26, 2025.
• Earnings Per Share (EPS): The EPS is reported as -$0.28.
• Shares Outstanding: There are 42,084,264 shares outstanding.

Here is a summary of Scopus BioPharma Inc.'s key valuation metrics:

Considering these metrics, investors should conduct thorough research and possibly consult with a financial advisor before making any investment decisions regarding Scopus BioPharma Inc. (SCPS). For additional details, you can refer to: Breaking Down Scopus BioPharma Inc. (SCPS) Financial Health: Key Insights for Investors.

Scopus BioPharma Inc. (SCPS) Risk Factors

Understanding the risks associated with Scopus BioPharma Inc. (SCPS) is crucial for investors. These risks can stem from both internal and external factors, influencing the company's financial stability and future prospects. Key areas of concern include industry competition, regulatory changes, and overall market conditions. Analyzing these factors provides a comprehensive view of potential challenges facing SCPS.

Here's an overview of the risk landscape:

• Industry Competition: The biopharmaceutical industry is highly competitive. SCPS faces competition from established pharmaceutical companies and other biotech firms, some of which have greater financial and research resources. This competition can impact the company's ability to successfully develop, commercialize, and market its products.
• Regulatory Changes: The development and marketing of biopharmaceutical products are subject to extensive regulation by governmental authorities, including the FDA in the United States. Changes in regulatory requirements or delays in obtaining regulatory approvals can significantly affect SCPS's operations and financial results.
• Market Conditions: Unfavorable market conditions, such as economic downturns or changes in healthcare spending, can negatively impact the demand for SCPS's products. Additionally, shifts in investor sentiment towards the biotechnology sector can affect the company's stock valuation and ability to raise capital.

Operational, financial, and strategic risks are often detailed in the company's earnings reports and filings. These documents provide insights into specific challenges identified by SCPS management. Investors should carefully review these reports to understand the company's assessment of its risk exposure. Mitigation strategies, if available, outline the company's plans to address these risks, which can include diversifying product offerings, strengthening intellectual property protection, and implementing cost-control measures.

Examples of specific risks and mitigation strategies may include:

• Clinical Trial Risks: The success of SCPS's product pipeline depends on the outcome of clinical trials. Unfavorable trial results or delays in enrollment can lead to significant setbacks and financial losses. Mitigation strategies may involve rigorous trial design, patient recruitment efforts, and adaptive trial protocols.
• Financing Risks: Biopharmaceutical companies often require substantial capital to fund research and development activities. SCPS may face challenges in securing financing on favorable terms, particularly if market conditions are unfavorable. Mitigation strategies may include exploring strategic partnerships, securing government grants, and managing cash flow effectively.
• Intellectual Property Risks: Protecting intellectual property is critical for SCPS's long-term success. The company may face risks related to patent infringement, trade secret misappropriation, or challenges to the validity of its patents. Mitigation strategies may involve actively monitoring and enforcing its intellectual property rights, seeking patent protection for new inventions, and implementing robust confidentiality agreements.

For more insights into the company's mission, vision, and core values, refer to: Mission Statement, Vision, & Core Values of Scopus BioPharma Inc. (SCPS).

Here's a hypothetical example of how these risks and mitigations might be presented in a structured format:

By understanding these risks and the company's strategies to mitigate them, investors can make more informed decisions about investing in Scopus BioPharma Inc. (SCPS). Continuous monitoring of company filings and industry news is essential for staying updated on the evolving risk landscape.

Scopus BioPharma Inc. (SCPS) Growth Opportunities

For investors eyeing Scopus BioPharma Inc. (SCPS), understanding the company's potential for future growth is crucial. Several factors can influence its trajectory, including innovative product development, strategic market expansion, and calculated acquisitions.

While specific revenue growth projections and earnings estimates for Scopus BioPharma Inc. (SCPS) aren't readily available in the provided search results, here's an overview of elements that generally drive growth in the biopharmaceutical industry:

• Product Innovation: Pharmaceutical companies thrive on the development and successful commercialization of new drugs and therapies.
• Market Expansion: Entering new geographic markets or expanding the use of existing products into new patient populations can significantly boost revenue.
• Strategic Partnerships and Acquisitions: Collaborations with other companies or acquiring promising technologies can accelerate growth and diversify product offerings.

To gain a clearer picture of Scopus BioPharma Inc.'s (SCPS) specific growth prospects, investors should consider the following approaches:

• Reviewing Official Company Documents: Scour BioPharma Inc.'s (SCPS) annual reports, investor presentations, and SEC filings (like 10-K and 10-Q reports) often contain detailed discussions of future strategies and financial forecasts.
• Analyzing Clinical Trial Data: Keep tabs on the progress and results of Scopus BioPharma Inc.'s (SCPS) clinical trials, as positive outcomes can significantly impact the company's valuation and future revenue potential.
• Monitoring Industry News: Stay informed about Scopus BioPharma Inc.'s (SCPS) partnerships, collaborations, and any regulatory approvals that could affect its growth trajectory.

Furthermore, keep in mind the competitive landscape. Scopus BioPharma Inc.’s (SCPS) ability to carve out a niche and maintain a competitive edge through unique offerings or strategic advantages will be vital for sustained growth.

Here is a link to more information: Breaking Down Scopus BioPharma Inc. (SCPS) Financial Health: Key Insights for Investors